ATE289516T1 - Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie - Google Patents

Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie

Info

Publication number
ATE289516T1
ATE289516T1 AT00928604T AT00928604T ATE289516T1 AT E289516 T1 ATE289516 T1 AT E289516T1 AT 00928604 T AT00928604 T AT 00928604T AT 00928604 T AT00928604 T AT 00928604T AT E289516 T1 ATE289516 T1 AT E289516T1
Authority
AT
Austria
Prior art keywords
combination
interferon alpha
pegylated interferon
ccr5 antagonist
hiv therapy
Prior art date
Application number
AT00928604T
Other languages
English (en)
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE289516T1 publication Critical patent/ATE289516T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00928604T 1999-05-04 2000-05-01 Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie ATE289516T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04
PCT/US2000/011634 WO2000066141A2 (en) 1999-05-04 2000-05-01 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Publications (1)

Publication Number Publication Date
ATE289516T1 true ATE289516T1 (de) 2005-03-15

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00928604T ATE289516T1 (de) 1999-05-04 2000-05-01 Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie

Country Status (21)

Country Link
EP (1) EP1175224B1 (de)
JP (1) JP2002543144A (de)
CN (1) CN1349408A (de)
AR (1) AR023824A1 (de)
AT (1) ATE289516T1 (de)
AU (1) AU776541B2 (de)
BR (1) BR0010593A (de)
CA (1) CA2365900A1 (de)
DE (1) DE60018273T2 (de)
ES (1) ES2238277T3 (de)
HK (1) HK1039278B (de)
HU (1) HUP0202734A3 (de)
MX (1) MXPA01011116A (de)
MY (1) MY127670A (de)
NO (1) NO328679B1 (de)
NZ (1) NZ514519A (de)
PE (1) PE20010283A1 (de)
PT (1) PT1175224E (de)
TW (1) TWI289454B (de)
WO (1) WO2000066141A2 (de)
ZA (1) ZA200108870B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
EP2385040A1 (de) 2003-03-14 2011-11-09 ONO Pharmaceutical Co., Ltd. Stickstoffhaltige heterocyclische Derivate und Arzneimittel, die diese als Wirkstoff enthalten
EP1616862A4 (de) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co Stickstoffhaltige heterocyclische verbindung und deren verwendung
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
ATE374838T1 (de) 2004-04-29 2007-10-15 Hoffmann La Roche Nukleotidsequenzvariation im gen ns5a als marker
EP2546234A1 (de) 2004-09-13 2013-01-16 Ono Pharmaceutical Co., Ltd. Stickstoffhaltige heterocyclische Derivate und Medizin damit als ein Wirkstoff
BRPI0609251A2 (pt) * 2005-02-23 2010-03-09 Schering Corp derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas
EP1889622A4 (de) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
AU2007225836A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
JP5245827B2 (ja) 2006-07-31 2013-07-24 小野薬品工業株式会社 スピロ結合した環状基を含有する化合物およびその用途
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013072705A1 (en) 2011-11-18 2013-05-23 Heptares Therapeutics Limited Muscarinic m1 receptor agonists
CN105899219B (zh) 2014-01-08 2021-08-13 免疫创新治疗有限公司 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU5522498A (en) * 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
PE20010283A1 (es) 2001-03-16
EP1175224B1 (de) 2005-02-23
PT1175224E (pt) 2005-07-29
MY127670A (en) 2006-12-29
ZA200108870B (en) 2003-03-26
EP1175224A2 (de) 2002-01-30
NO20015367D0 (no) 2001-11-02
AU776541B2 (en) 2004-09-16
HUP0202734A3 (en) 2003-11-28
HK1039278B (en) 2005-06-30
DE60018273T2 (de) 2005-08-18
BR0010593A (pt) 2002-02-13
CN1349408A (zh) 2002-05-15
DE60018273D1 (de) 2005-03-31
NO328679B1 (no) 2010-04-26
JP2002543144A (ja) 2002-12-17
CA2365900A1 (en) 2000-11-09
HUP0202734A2 (hu) 2002-12-28
ES2238277T3 (es) 2005-09-01
TWI289454B (en) 2007-11-11
AR023824A1 (es) 2002-09-04
WO2000066141A3 (en) 2001-02-08
AU4681500A (en) 2000-11-17
NO20015367L (no) 2002-01-03
WO2000066141A2 (en) 2000-11-09
MXPA01011116A (es) 2002-06-04
HK1039278A1 (en) 2002-04-19
NZ514519A (en) 2003-07-25

Similar Documents

Publication Publication Date Title
ATE289516T1 (de) Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv therapie
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
AT386517B (de) Stuhl, insbesondere arbeitsstuhl
ATE263242T1 (de) Aminoterminal verkürztes rantes als chemokin antagonist
PT1268396E (pt) Eteres difenilicos utilizados em terapeutica
NO942343L (no) Farmasöytisk preparat med analgetisk aktivitet
IT8840094A0 (it) Elevatore, in particolare per carichi palettizzati
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
IL114655A (en) USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
IT8733505V0 (it) Montante in particolare per carrelli,con i cilindri di sollevamento incoroporati nei profili
HUP0002329A3 (en) New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy
DK0815126T3 (da) Bicykliske tachykinin-antagonister, fremstilling deraf og deres anvendelse i farmaceutiske præparater
DK1175224T3 (da) Pegyleret interferon-alfa i kombination med en CCR5-antagonist til HIV-terapi
NO20011371D0 (no) Kjemokinreseptorantagonist og cyklosporin i kombinert terapi
SE8504931D0 (sv) Lyftkrok for armeringsmattor, vilken skall anvendas vid byggnadsarbeten mm
ITMI992691A0 (it) Gru automontante con rotazione in basso per cantieri edili
TW392472U (en) Structural improvement in chair
ITPI990002A0 (it) Segatrice con tavola semovente in senso verticale
GB9901615D0 (en) Improvements in or relating to antimalarial agents
BR7201262U (pt) Mesa de pedra com base estruturada em forma de cabide
AU138995S (en) Pool/billiard table top
TW320075U (en) Golf practicing structure designed in billiard table configuration
GB8927288D0 (en) Improvements in sabre fencing hit direction
ITMI992256A0 (it) Complessi di rutenio con elevata attivita' antitumorale
SE9600803D0 (sv) Personlyft i badkar

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1175224

Country of ref document: EP

REN Ceased due to non-payment of the annual fee